Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial
Douglas R. Adkins(Washington University in St. Louis), Peter Oppelt(Washington University in St. Louis), Jessica Ley(Washington University in St. Louis), Francis P. Worden(Georgetown University), Ronald J. Maggiore, Nabil F. Saba(Emory University), Noha N. Salama(Cairo University), Kathryn Trinkaus(Washington University in St. Louis), Assuntina G. Sacco(University of California San Diego), Juneko E. Grilley‐Olson(University of North Carolina at Chapel Hill), Conor Steuer(Emory University), Kevin Palka(Washington University in St. Louis), Prakash Neupane(University of Kansas Medical Center), Brian A. Van Tine(Washington University in St. Louis)
Cited by 125
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Head and neck cancer
|The Lancet|2021|829